Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

7

Sep 2026

GLP-1 drugs looked promising for depression. The evidence tells a more complicated story

A systematic review of 43 studies found highly heterogeneous results for GLP-1 receptor agonists across animal models and human research assessing depression-, anxiety-, and stress-related outcomes. No study directly tested these drugs as a treatment for PTSD, and the available evidence does not currently support their use for depression or PTSD, although people with metabolic dysfunction may warrant further investigation.

Psilocybin microdosing sounds promising, but the strongest studies tell a different story

7

Sep 2026

Psilocybin microdosing sounds promising, but the strongest studies tell a different story

A systematic review of 11 studies involving 3,262 adults found that psilocybin mushroom and truffle microdosing was associated with reported improvements across areas including mental health, well-being, cognition, creativity, and social functioning. However, the evidence was methodologically weak and highly heterogeneous, the two placebo-controlled trials found no significant improvements, and inadequate adverse-event reporting means efficacy and safety remain uncertain.

What mothers eat in pregnancy may shape a child’s weight years later

7

Sep 2026

What mothers eat in pregnancy may shape a child’s weight years later

A prospective study of 252 mother-child pairs found that higher combined maternal fruit and vegetable intake during pregnancy was associated with lower odds of overweight or obesity in children at age four. Total and natural fruit juice showed no association, whereas higher commercial fruit juice intake was associated with increased odds, though the authors emphasized that this finding was exploratory.

AI-designed drug candidate reverses biological age in clinical study

7

Sep 2026

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Mercury Pharmaceuticals
Mercury Pharmaceuticals

Why Us?

KNOWLEDGE OF RESEARCH ENVIRONMENT

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.

UNDERSTANDING INDUSTRIAL NEEDS

Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.

FOCUSED PROJECT MANAGEMENT

Smart approach to project management that helps speed up development stages and decision making.

INVESTMENT CAPABILITY

Availability of own investment up to 2m€ per project allows us to reach the next value milestone.